<DOC>
	<DOCNO>NCT00004009</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . PURPOSE : Phase I trial study effectiveness R115777 treat patient refractory recurrent acute leukemia chronic myelogenous leukemia .</brief_summary>
	<brief_title>R115777 Treating Patients With Refractory Recurrent Acute Leukemia Chronic Myelogenous Leukemia</brief_title>
	<detailed_description>OBJECTIVES : I . Determine toxicities pharmacokinetics oral R115777 adult refractory acute leukemia accelerate blastic phase chronic myelogenous leukemia . II . Determine effect R115777 farnesylation within leukemia cell . III . Determine clinical response ( least 50 % decrease circulate leukemia cell ) R115777 patient . OUTLINE : This dose escalation , multicenter study . Patients receive oral R115777 7-21 day . Patients achieve complete response ( CR ) partial response ( PR ) follow 1-4 course treatment may receive 4 additional course . Patients stable disease may receive another 7-21 day course . If CR PR achieve , patient may receive 4 additional course . Cohorts 6-12 patient receive escalate dos R115777 maximum tolerate dose ( MTD ) determine . The MTD define dose 17 % 33 % patient experience dose limit toxicity . PROJECTED ACCRUAL : A total 24 patient accrue study within 2 year .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Tipifarnib</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically proven leukemia follow type : Acute myelogenous leukemia ( AML ) Newly diagnose de novo AML patient 60 year poor risk feature Antecedent hematologic disorder Complex karyotypes adverse cytogenetics Stem cell immunophenotype AML arise myelodysplastic syndrome Secondary AML Recurrent refractory AML , include primary induction failure Acute lymphoblastic leukemia ( ALL ) Newly diagnose de novo ALL patient 60 year poor risk disease feature Complex karyotype adverse cytogenetics Mixed lineage immunophenotype Recurrent refractory ALL , include primary induction failure Chronic myelogenous leukemia accelerate phase blast crisis No 2 prior induction/reinduction therapy course fail primary induction therapy relapse follow complete remission Not eligible refuse allogeneic bone marrow transplantation Acute progranulocytic leukemia ( M3 ) must meet following criterion : Prior treatment tretinoin require No coagulopathy Low risk develop coagulopathy No disseminate intravascular coagulation No CNS leukemia PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : Not specify Hematopoietic : No hyperleukocytosis ( least 50,000 leukemic blasts/mm3 ) Hepatic : Bilirubin normal SGOT SGPT great 2 time normal Renal : Creatinine great 2 time normal Cardiovascular : LVEF least 45 % MUGA echocardiogram No myocardial infarction within past 3 month No severe coronary artery disease No cardiomyopathy No congestive heart failure No prior coagulation relate sequela : Deep vein thrombosis Pulmonary embolus CNS thrombosis bleed Other : No pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : At least 1 week since prior growth factor ( epoetin alfa , filgrastim , sargramostim , interleukin3 , interleukin11 ) recover No prior allogeneic bone marrow transplantation No concurrent immunotherapy Chemotherapy : See Disease Characteristics At least 3 week since prior chemotherapy recover No concurrent chemotherapy Endocrine therapy : At least 3 week since prior endocrine therapy recover Radiotherapy : At least 3 week since prior radiotherapy recover No prior extensive radiotherapy great 25 % bone marrow No concurrent radiotherapy Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
	<keyword>recurrent adult acute lymphoblastic leukemia</keyword>
	<keyword>accelerated phase chronic myelogenous leukemia</keyword>
	<keyword>blastic phase chronic myelogenous leukemia</keyword>
	<keyword>untreated adult acute lymphoblastic leukemia</keyword>
	<keyword>untreated adult acute myeloid leukemia</keyword>
	<keyword>adult acute promyelocytic leukemia ( M3 )</keyword>
	<keyword>secondary acute myeloid leukemia</keyword>
</DOC>